List of Excipients in Branded Drug ARAVA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
sanofi-aventis US LLC	ARAVA	leflunomide	0088-2160	CROSPOVIDONE
sanofi-aventis US LLC	ARAVA	leflunomide	0088-2160	HYPROMELLOSE
sanofi-aventis US LLC	ARAVA	leflunomide	0088-2160	LACTOSE MONOHYDRATE
sanofi-aventis US LLC	ARAVA	leflunomide	0088-2160	MAGNESIUM STEARATE
sanofi-aventis US LLC	ARAVA	leflunomide	0088-2160	POLYETHYLENE GLYCOL

Last updated: August 2, 2026

ARAVA is a mature leflunomide product with no meaningful brand-driven exclusivity barrier in the U.S. The commercial opportunity is therefore concentrated in lower-cost generic supply, differentiated excipient systems, pediatric and extemporaneous formulations, and formulations designed to improve tolerability, manufacturability, or global regulatory access. The strongest opportunities are incremental, not premium-priced replacement products.

ARAVA Excipient Strategy and Commercial Opportunities for Leflunomide

What is ARAVA and which formulation does it use?

ARAVA is the brand name for leflunomide, an oral disease-modifying antirheumatic drug approved for active rheumatoid arthritis in adults. Leflunomide is converted to teriflunomide, its active metabolite, which inhibits dihydroorotate dehydrogenase and reduces activated lymphocyte proliferation.[1]

The U.S. product is supplied as immediate-release film-coated tablets in 10 mg, 20 mg, and 100 mg strengths. The 100 mg tablet is used as a loading dose, while the 20 mg tablet is the usual maintenance strength. The 10 mg tablet is used when dose reduction is needed.[1]

ARAVA dosage forms and strength profile

Product	Strength	Principal clinical role	Excipient strategy implication
ARAVA tablet	10 mg	Reduced-dose maintenance	Low-dose content uniformity is critical
ARAVA tablet	20 mg	Standard maintenance dose	Primary generic volume opportunity
ARAVA tablet	100 mg	Loading dose	Lower annual unit demand; high-dose tablet size and disintegration matter

The original ARAVA tablet formulation uses conventional solid-dose excipients, including lactose monohydrate, corn starch, povidone, crospovidone, colloidal silicon dioxide, magnesium stearate, talc, and film-coating components. Exact inactive-ingredient composition can vary by market and manufacturer.[1,2]

The formulation is commercially important because leflunomide is a small-molecule immediate-release product. It does not require the complex delivery systems associated with biologics, long-acting injectables, or modified-release oral products.

What excipients are used in ARAVA tablets?

The core excipient system is a conventional wet-granulation or direct-compression platform built around a diluent, binder, disintegrant, glidant, and lubricant.

Core excipient functions

Excipient class	Typical ARAVA role	Commercial and technical relevance
Lactose monohydrate	Diluent	Supports tablet mass and compressibility
Corn starch	Diluent and disintegrant	Helps tablet breakup and processability
Povidone	Binder	Improves granule and tablet strength
Crospovidone	Superdisintegrant	Supports immediate release
Colloidal silicon dioxide	Glidant	Controls powder flow
Magnesium stearate	Lubricant	Reduces sticking and ejection force
Talc	Processing or coating aid	Supports manufacturability and film coating
Hypromellose	Film former	Provides tablet coating
Titanium dioxide and iron oxides	Colorants or opacifiers	Enable strength identification and product appearance

The principal formulation constraint is not a complex release mechanism. It is the need to reproduce rapid and consistent dissolution while maintaining content uniformity at the 10 mg strength.

Leflunomide is practically insoluble in water, making particle size, wetting, granulation, and disintegration relevant to dissolution performance. A formulation that reduces lubricant sensitivity or improves wetting can create manufacturing value without changing the therapeutic dose.[1,3]

What excipient strategies can differentiate a leflunomide generic?

The most practical strategies involve replacing selected excipients while preserving immediate release and bioequivalence.

Lactose-free formulations

A lactose-free formulation can address patients with lactose intolerance and support procurement policies that restrict animal-derived or dairy-derived ingredients. Potential replacements include microcrystalline cellulose, mannitol, dibasic calcium phosphate, or selected co-processed excipients.

The commercial benefit is limited in standard adult rheumatoid arthritis because lactose intolerance is not a dominant prescribing driver. The opportunity is stronger in hospital, institutional, and international markets where excipient declarations influence formulary selection.

The technical risks include:

• Different tablet density and weight;
• Changes in compactibility;
• Altered disintegration time;
• Increased tablet size;
• Different moisture behavior;
• New elemental impurity or nitrosamine control requirements, depending on the supplier and process.

Starch-free or low-starch formulations

Replacing corn starch with crospovidone, sodium starch glycolate, or a co-processed filler-disintegrant can improve supply flexibility and produce a smaller tablet. A starch-free product may also simplify global excipient declarations.

The main development target is not a new clinical effect. It is process robustness, especially tablet hardness, friability, disintegration, and dissolution after accelerated stability storage.

Low-magnesium-stearate formulations

Magnesium stearate can slow dissolution when over-lubrication creates hydrophobic particle surfaces. A low-level lubricant strategy, shorter lubrication time, or use of sodium stearyl fumarate can improve dissolution robustness.

This strategy may be valuable where the active pharmaceutical ingredient has poor wettability. It requires tight control of blending time, lubricant concentration, and scale-up conditions.

Moisture-controlled formulations

Leflunomide products should be evaluated for moisture sensitivity, polymorphic behavior, and dissolution changes during storage. A lower-moisture formulation can use:

• Reduced-water granulation;
• Dry granulation;
• High-barrier blister packaging;
• Desiccant-containing bottles;
• Moisture-resistant film coatings;
• Excipients with controlled water activity.

Packaging can be as commercially important as the excipient change. A robust low-cost bottle may outperform a technically superior formulation that requires expensive blister packaging.

Color and identification strategy

The 10 mg, 20 mg, and 100 mg strengths require reliable visual differentiation. Colorant selection can be optimized for:

• Strength recognition;
• Photostability;
• Global regulatory acceptability;
• Reduced titanium dioxide exposure;
• Consistent appearance across manufacturing sites.

A color-free or titanium-dioxide-free product may appeal to selected markets, but the commercial premium is generally small unless it reduces regulatory or supply-chain friction.

What formulation patents protect ARAVA or leflunomide products?

ARAVA’s principal commercial protection was based on legacy composition, use, and product patents associated with leflunomide. Those rights are now expired or commercially exhausted in the major generic markets.

The relevant patent landscape should be separated into four categories:

Patent category	Relevance to ARAVA	Current commercial significance
Leflunomide composition-of-matter patents	Protected the active compound	Expired
Basic tablet formulation patents	Covered conventional oral dosage forms	Generally expired
Method-of-use patents	Covered treatment of rheumatoid arthritis and related conditions	Largely expired or weak against routine generic use
New formulation patents	Could cover solubility, modified release, pediatric dosing, or combination products	Potentially relevant only for newly developed products

A new excipient combination is not automatically patentable. A viable patent position normally requires a non-obvious formulation, a defined performance advantage, or an unexpected technical result. Simple substitution of lactose with microcrystalline cellulose is unlikely to support a strong standalone patent unless it produces a demonstrated and claimed benefit.

Potentially stronger claim categories include:

• A defined particle-size distribution;
• A specific dissolution profile;
• A low-impurity or low-degradation formulation;
• A moisture-stable dosage form;
• A pediatric liquid or dispersible formulation;
• A formulation that improves content uniformity at 10 mg;
• A manufacturing process that reduces batch failure or improves scale-up;
• A combination of excipients that produces an unexpected dissolution or stability result.

When does ARAVA lose exclusivity and what is its Orange Book status?

ARAVA lost practical market exclusivity years ago. FDA approved ARAVA in 1998, and generic leflunomide tablets entered the U.S. market after the relevant brand exclusivity and patent barriers expired.[1,4]

U.S. regulatory timeline

Event	Approximate date	Commercial effect
FDA approval of ARAVA	1998	Originator launch
Brand market protection period	Late 1990s to early 2000s	Delayed ANDA competition
Relevant basic patent period	Expired before current market maturity	Removed composition-level barrier
Generic leflunomide approvals	From the late 2000s onward	Established multi-source competition
Current market	Mature generic market	Price and supply reliability dominate

The Orange Book remains relevant for verifying any active listed patents, exclusivity codes, therapeutic-equivalence evaluations, and approved strengths. For a mature leflunomide product, the principal regulatory issue is generally ANDA approval and therapeutic equivalence rather than a live ARAVA patent barrier.[4]

A formulation company should not assume that a differentiated excipient system receives independent market exclusivity. An ANDA with a changed inactive-ingredient profile generally remains a generic product if it meets the applicable sameness, safety, quality, and bioequivalence requirements.

What Paragraph IV challenges and litigation affect ARAVA?

Leflunomide has been subject to the standard generic-entry pattern for an off-patent small molecule. ANDA applicants could challenge any remaining listed patents through Paragraph IV certifications, while later applicants could rely on Paragraph III certifications or submit applications after patent expiration.

No current ARAVA litigation barrier is central to the commercial strategy for generic leflunomide. The key legal exposure is instead product-specific:

• Infringement risk from any newly issued formulation patent;
• Patent-term interpretation for a new pediatric or liquid formulation;
• Trade-secret protection around manufacturing parameters;
• Regulatory exclusivity attached to a novel clinical investigation;
• Labeling disputes involving patented methods of use;
• Supplier rights concerning co-processed excipients or proprietary excipient systems.

A generic manufacturer should conduct a current Orange Book and litigation review before launch. The risk is more likely to arise from a newly developed formulation or manufacturing patent than from the original ARAVA product estate.

Is there biosimilar risk for ARAVA?

There is no biosimilar pathway for ARAVA because leflunomide is a chemically synthesized small molecule, not a biologic. Competition occurs through abbreviated new drug applications, not biosimilar applications.

The relevant competitors are generic leflunomide tablets and, to a lesser extent, alternative disease-modifying antirheumatic drugs such as methotrexate, sulfasalazine, hydroxychloroquine, and biologic therapies used after inadequate response to conventional treatment.[5]

Leflunomide also competes indirectly with teriflunomide products used in multiple sclerosis. Teriflunomide is the active metabolite of leflunomide, but it is a separate drug product with a different indication, regulatory history, labeling profile, and commercial market.

Which companies are competing in the leflunomide market?

The U.S. market has historically included generic suppliers such as Teva, Mylan or Viatris, Apotex, Dr. Reddy’s Laboratories, and other ANDA holders, depending on the strength and period reviewed. Supplier participation changes over time as manufacturers withdraw, consolidate, or adjust portfolios.

Competition is based on:

1. Unit price;
2. Reliable API supply;
3. FDA manufacturing compliance;
4. National contract coverage;
5. Product availability in all three strengths;
6. Packaging cost;
7. Wholesaler and group-purchasing relationships.

A supplier with only the 20 mg strength may capture volume but lose formulary access where hospitals require the complete strength set. The 100 mg loading-dose strength has lower recurring demand but can improve portfolio completeness.

What commercial opportunities exist for ARAVA excipient suppliers?

The largest opportunities are in supply-chain substitution and differentiated generic development.

Excipient substitution for cost and supply security

Excipient suppliers can target replacement of:

• Lactose monohydrate;
• Corn starch;
• Povidone;
• Crospovidone;
• Magnesium stearate;
• Film-coating systems.

A co-processed excipient can offer value if it reduces manufacturing steps, improves flow, lowers tablet weight, or reduces dissolution variability. The customer decision will depend on total cost per released batch, not only excipient price.

Pediatric and liquid formulations

The strongest unmet formulation opportunity is a patient-appropriate dosage form for children or patients unable to swallow tablets. Leflunomide is not routinely positioned as a pediatric rheumatoid arthritis product in the same way as some established pediatric therapies, and the drug’s safety profile creates substantial development and regulatory complexity.[1]

Potential products include:

• Oral suspension;
• Powder for reconstitution;
• Dispersible tablet;
• Sprinkle formulation;
• Small-dose tablet;
• Extemporaneous-compounding kit.

These products could support a 505(b)(2) strategy if they rely on new clinical or bridging work and offer a meaningful administration benefit. The development burden is higher than for a conventional ANDA.

Hospital and specialty packaging

A unit-dose blister, calendar pack, or low-volume bottle could improve medication management. The opportunity is strongest in institutional settings rather than broad retail pharmacies.

Packaging claims may include moisture protection, child resistance, unit-dose handling, or improved dose differentiation. These features are more likely to create commercial differentiation than a routine change in tablet filler.

Global-market formulations

Excipient systems designed for multiple jurisdictions can reduce regulatory complexity. A global formulation should address:

• Different permitted colorants;
• Titanium dioxide restrictions or market preferences;
• Animal-derived materials;
• Lactose declarations;
• Gluten-related labeling;
• Nitrosamine risk from raw materials;
• Residual solvents;
• Elemental impurities;
• Local pharmacopoeial requirements.

A single formulation that can be registered in the U.S., European Union, Japan, and emerging markets can reduce technical-transfer costs, although local bioequivalence and excipient requirements still apply.

How strong is the patent estate for a new leflunomide formulation?

The original ARAVA patent estate is weak as a barrier to generic entry because the product is mature and genericized. A new formulation could create a narrower patent position, but the strength would depend on claim scope and clinical or technical differentiation.

Relative patent strength by opportunity

Opportunity	Expected patent strength	Commercial assessment
Lactose-free tablet	Low	Useful for procurement and patient preference
Starch-free tablet	Low to moderate	Stronger if tied to process or dissolution benefit
New film coat	Low	Usually a limited differentiation tool
Low-moisture tablet	Moderate	Potential value if stability data show a clear advantage
Pediatric dispersible tablet	Moderate to strong	Requires regulatory and clinical development
Oral suspension	Moderate	Potential 505(b)(2) opportunity
Modified-release leflunomide	Moderate to strong	Requires clinical justification and safety assessment
Combination product	Stronger if clinically justified	Higher development and regulatory burden
Manufacturing process	Moderate	Can protect know-how even when product claims are narrow

Trade secrets may provide more practical value than patents for granulation endpoint, blending sequence, lubrication time, compression force, and coating parameters. These controls can reduce batch failures without exposing the process to public patent disclosure.

What FDA regulatory pathway applies to a new ARAVA formulation?

A conventional immediate-release generic tablet normally uses an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence and comply with FDA requirements for inactive ingredients, quality, labeling, and manufacturing.[4,6]

A materially different dosage form may require a 505(b)(2) application. Examples include:

• Oral suspension;
• Modified-release tablet;
• Novel dispersible dosage form;
• New route of administration;
• New indication;
• Formulation requiring clinical bridging.

Excipient changes in an ANDA must not compromise safety, performance, or bioequivalence. FDA’s product-specific guidance and dissolution expectations should guide development. The formulation should be tested across all strengths, with particular attention to the 10 mg tablet because low drug loading increases content-uniformity risk.[6]

What generic launch scenarios exist for leflunomide?

Low-cost conventional tablet

This is the most likely launch model. It offers the lowest development cost but faces severe price competition and limited differentiation.

Premium supply-secure generic

A manufacturer can position a product around dual API sourcing, domestic packaging, reliable all-strength availability, and low back-order risk. This model may support better contract economics without requiring a novel dosage form.

Differentiated excipient tablet

A lactose-free, low-moisture, or smaller tablet may achieve preferred status with selected buyers. The opportunity depends on documented performance rather than excipient novelty alone.

505(b)(2) patient-convenience product

A liquid, dispersible, or pediatric formulation could support a more defensible commercial position. It would require greater investment, clinical and regulatory work, and careful management of leflunomide’s boxed-warning and reproductive-risk considerations.[1]

International low-cost platform

A globally standardized tablet can create value through registration efficiency and supply-chain scale. The primary competitive advantage is operational rather than patent-based.

What revenue exposure does ARAVA create for Sanofi and generic manufacturers?

ARAVA is a mature product and does not have the revenue profile of an actively protected specialty medicine. Brand revenue exposure is therefore limited relative to Sanofi’s newer immunology and specialty-care products.

For generic manufacturers, revenue depends on:

• Number of approved suppliers;
• Channel concentration;
• Contract duration;
• API cost;
• Manufacturing yield;
• Product availability;
• Strength coverage;
• Reimbursement and substitution policy.

The 20 mg tablet is likely to represent the largest recurring unit opportunity because it corresponds to the standard maintenance dose. The 100 mg tablet is strategically useful but less attractive as a standalone product. The 10 mg tablet can support dose-reduction and tolerability management but has lower volume.

A formulation company should model contribution margin by strength rather than evaluate the product only on total prescription volume.

Key Takeaways

• ARAVA is leflunomide, an immediate-release oral tablet for rheumatoid arthritis.
• The standard formulation uses conventional excipients, including lactose, starch, povidone, crospovidone, silica, magnesium stearate, and film-coating materials.
• ARAVA’s original patent and exclusivity barriers are no longer a meaningful obstacle to generic entry.
• There is no biosimilar pathway because leflunomide is a small molecule.
• The strongest near-term opportunities are lactose-free formulations, moisture-controlled tablets, supply-secure generic manufacturing, and global excipient standardization.
• Pediatric, liquid, and dispersible products offer greater differentiation but may require a 505(b)(2) strategy.
• Routine excipient substitution has limited patent strength unless supported by unexpected technical performance.
• The 20 mg tablet is the main volume opportunity; the 10 mg and 100 mg strengths improve portfolio completeness.
• Manufacturing know-how may provide greater practical protection than broad formulation patents.
• Current Orange Book entries, ANDA approvals, and litigation should be checked before a commercial launch decision.

FAQs About ARAVA Excipient Strategy and Leflunomide Commercialization

Is ARAVA lactose-free?

The original ARAVA tablet formulation includes lactose monohydrate in the U.S. labeling. Generic products may use different inactive ingredients, so lactose-free status must be verified against each manufacturer’s label.[1]

Can a generic company change ARAVA’s excipients?

Yes. An ANDA applicant can use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, quality, dissolution, and labeling.[4,6]

Is leflunomide suitable for an extended-release formulation?

A modified-release formulation is technically possible but would require a clinical and regulatory rationale. The long persistence of teriflunomide and the drug’s safety profile make dose control and clinical bridging important development issues.[1]

Does a new leflunomide excipient combination receive market exclusivity?

Usually not. A new excipient combination may support a patent if it is novel, non-obvious, and supported by technical results, but ordinary excipient substitution generally does not create meaningful regulatory exclusivity.

Is a leflunomide oral suspension a commercial opportunity?

It can be, particularly for patients who cannot swallow tablets or for specialized populations. The opportunity carries higher formulation, stability, dosing-accuracy, palatability, clinical, and regulatory requirements than a conventional generic tablet.

References

1. U.S. Food and Drug Administration. (2019). Arava (leflunomide) tablets: Prescribing information. Sanofi-Aventis U.S. LLC.

2. European Medicines Agency. (2023). Arava: Summary of product characteristics. European Medicines Agency.

3. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

5. American College of Rheumatology. (2021). 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care & Research, 73(7), 924-939.

6. U.S. Food and Drug Administration. (2017). Guidance for industry: ANDAs for certain highly variable immediate-release solid oral dosage forms. FDA, Center for Drug Evaluation and Research.